Contemporary disease diagnosis often relies on the histological analysis of surgically excised or biopsied specimens [
1]. However, traditional two-dimensional (2D) histological workflow yields 2D slides of the samples, bringing with it huge limitations [
1,
2], such as undersampling-induced limited reliability, insufficient accuracy and reproductivity, and the time-wasting and destructive workflow. Therefore, the concept of three-dimensional (3D) histology emerges as demanded by the times. Conventional nonfluorescent histological stains (
e.g., hematoxylin and eosin (H&E)) lack the compatibility with the volumetric imaging, so fluorescence staining and imaging play an indispensable role in 3D histology. In the early cases, the 3D histology relies on the fluorescence imaging of proteins expressed from transgenes [
3,
4], such as green fluorescent protein, but the transgenic manipulation steps are time-consuming and only suitable for research goals rather than clinical applications [
5]. The use of fluorescently labeled antibodies avoids the genetic manipulation, but possesses other disadvantages, such as the inability to provide general pathological information, high cost, and slow thick tissue penetration [
6]. Autofluorescence of biological samples has also been used for fluorescence imaging, but its requirement of a strong excitation laser also seriously hampers its application together with other fluorescent labels [
7]. By contrast, small-molecule fluorescent stains present better tissue penetration ability and relatively stronger fluorescence intensity [
8-
10], but the affinity-based small-molecule fluorescent stains may lead to the production of uneven staining results in relatively thick tissues, and fluorescent stains with reactive functional groups are also relatively expensive and their nonspecific binding may generate false-positive readouts [
7]. To sum up, in 3D histology, the fluorescence staining and imaging of the thick tissues await technological innovation.